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Review
Evaluating the Species Barrier
Jean C. Manson and Abigail B. Diack
Neurobiology Division, The Roslin Institute and R(D)SVS, University of Edinburgh, Easter Bush, UK
A Transmissible Spongiform Encephalopathy (TSE) agent from one species generally transmits poorly to a new species, 
a phenomenon known as the species barrier. However once in the new species it generally but not always adapts and 
then more readily transmits within the new host. No single test is available to determine accurately the ability of a prion 
strain to transmit between species. Evaluating the species barrier for any prion strain has to take into consideration as 
much information as can be gathered for that strain from surveillance and research. The interactions of the agent with a 
particular host can be measured by in vivo and in vitro methods and assessing the species barrier needs to make full use 
of all the tools available. This review will identify the important considerations that need to be made when evaluating 
the species barrier.
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Surveillance
It is important for evaluating risk to animal and human health to be aware of the prion strains that are present 
within a species and to have a means of detecting novel forms of emerging diseases. Surveillance remains important 
in determining the extent of prion infection within a species. Animal surveillance in Europe following the outbreak of 
Bovine Spongiform Encephalopathy (BSE) has determined the extent of the problem and been important for monitor-
ing the decline in BSE following the implementation of the feed bans1,2). Moreover animal surveillance in cattle, sheep 
and goats has allowed the detection of atypical forms of both BSE and scrapie3,4). Surveillance has mapped the spread 
of Chronic Wasting Disease (CWD) from the west to the east of the USA and its spread into Canada5). Recent surveil-
lance in Norway has identified the first known cases of CWD in Europe6,7). Surveillance in humans has allowed the 
identification of variant Creutzfeldt-Jakob Disease (vCJD)8), has assessed variations in sporadic CJD (sCJD) numbers 
between countries9) and identified a new form of human prion disease namely Variably Protease-Sensitive Prionopathy 
(VPSPr)10). Ongoing surveillance is required to identify further cases of human prion disease that may occur in different 
genetic backgrounds, in “at risk” groups or in which diagnosis may be difficult due to confounding factors such as age 
or other neurodegenerative diseases.
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Strain Identification
Once a new form of disease has been identified it has to be established if this is indeed a new disease or one that has 
been present for some time. It is also important to establish whether there is any connection between the “new” strain 
and those already present in the field. Retrospective analysis of atypical scrapie has suggested that this is indeed not 
a new disease but has been detected in tissue from the 1970’s and has most likely come to light through the extensive 
European animal surveillance programme11). Similarly within human prion disease the recently identified VPSPr has 
now been shown to be present in much earlier cases suggesting it was indeed a previously unrecognised prion disease12).
Strains can be characterized by both in vitro and in vivo techniques but it is important to recognize that in vitro 
techniques alone are not sufficient for strain identification. In vivo strain identification is undertaken using a validated 
panel of either wild type or transgenic mice. Following inoculation a number of criteria are measured: the incubation 
time of disease, the vacuolar pathology and the PrP deposition in the brain at the end point of disease. The importance of 
the validated panel of mice is that one criteria for assessing strain is the order in which each strain of mice succumbs to 
disease, namely the ranking of incubation times; this provides important information for assessing the similarity and dif-
ferences between strains (Fig. 1)13). Full characterisation of a strain may require a number of sub-passages to overcome 
the species barrier and to allow stabilization of the strain.
Wild type mouse panels have proven invaluable in identifying the BSE strain and establishing the range of suscep-
tible hosts, i.e. humans, cats, exotic ungulates and primates13). They have also determined that a single BSE/vCJD strain 
is responsible for vCJD cases worldwide14) and provide a platform for further strain discrimination. In vivo strain typing 
using a variety of models has also identified a number of different strains of scrapie in the field15,16), and the probability 
of multiple strains of CWD17–19). A similar approach can be taken with panels of mice expressing the human PRNP gene. 
These have proven useful for strain typing human prion agents, identifying new diseases and assessing susceptibility to 
a particular agent of the different human host genotypes, in particular the PRNP codon 129 genotype. Using panels of 
gene-targeted transgenic mice in which the human PRNP gene has replaced the murine gene four strains of sCJD have 
been defined20); VPSPr has been shown to be a unique prion strain21) and assessment of vCJD infectivity and suscepti-
bility risks has been undertaken22,23).
There is a multiplicity of models of transgenic mice with Prnp genes carrying different mutations and from differ-
ent species. The transgenic mice range from multiple copies of Prnp genes inserted at random into the genome to trans-
genic mice produced by gene targeting replacing the endogenous murine Prnp gene for an alternative Prnp gene22,24). 
Fig. 1. Incubation period rankings can be a useful tool in assessing TSE strains. Ex-
amples of incubation periods from primary passage of experimental sheep BSE, FSE, BSE, 
vCJD and scrapie in three lines of wild type mice. Abbreviations: BSE, Bovine Spongiform 
Encephalopathy; FSE, Feline Spongiform Encephalopathy; vCJD, variant Creutzfeldt-Jakob 
disease.
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The differences between these lines should be considered when using them as tools for strain typing and for assessing 
the species barrier as the level of the PrP protein might alter the susceptibility of a host to a particular agent. The bank 
vole has also proven over recent years to be a useful model for strain determination due to its apparently universal per-
missibility to multiple prion strains25–27). In addition to traditional strain typing criteria, the glycosylation pattern of 
PrPSc can also be used as an indicator of a TSE strain as many but not all strains have a unique profile of di, mono and 
unglycosylated PrPSc28,29). Different strains may also display different properties when amplified in in vitro assay sys-
tems such as protein misfolding cyclic amplification (PMCA) and real time quaking induced conversion (RTQuIC). Use 
of these tools in combination with in vivo strain typing can thus provide a powerful method of strain typing.
Host /agent Determinants of Transmission
What defines the ability of a prion strain to transmit within or between species? Some transmit readily within and 
between species e.g. scrapie and CWD whereas some are very hard to transmit e.g. sCJD and some agents may not 
transmit at all between individuals. The only known zoonotic prion agent to date is BSE. Understanding the interaction 
between a host and agent is important in evaluating a species barrier but there are many aspects of this interaction that 
are not well understood.
While the route and dose of inoculum have some influence over the disease process many other aspects are also 
important. The ability of an agent to replicate in the periphery and to be transported from the periphery to the central 
nervous system (CNS) will influence its ability to sustain an infection. One of the most studied aspects of host suscep-
tibility is the Prnp genotype of the host and polymorphisms controlling susceptibility and resistance has been eluci-
dated for many species30–32). Prnp sequence similarity between host and agent often leads to high susceptibility and 
differences lead to enhanced resistance but this is not always a good predictor of transmission potential of a particular 
agent33,34). While some genotypes can provide resistance to one prion strain with a different strain these may be the most 
susceptible animals. This is particularly well portrayed in sheep with susceptibility and resistance to classical and atypi-
cal scrapie where the genotypes leading to resistance with one agent result in susceptibility to the other35). In humans, 
the codon 129 methionine/valine polymorphism in the human PRNP gene has been well studied in at both population 
level36), in infected humans32) and in experimental models and has been shown to influence both susceptibility and pa-
thology of disease22).
Defining Distribution of Infectivity and Routes of Transmission
Possible routes of transmission vary for host agent combinations for example BSE in cattle affects the CNS but 
shows little involvement of the peripheral tissues. The oral route of transmission through infected meat is therefore con-
sidered the most likely manner in which humans acquired vCJD. However when BSE was experimentally transmitted 
to sheep both CNS and peripheral tissues harbored infectivity37) and BSE transmission to humans in the form of vCJD 
has shown a very different distribution of infectivity to that of BSE in cattle38–41). This widespread distribution of in-
fectivity in humans has led to transmission of infectivity through blood transfusion which has been demonstrated both 
experimentally42–46) and in patients with vCJD47–49). Indeed the blood transfusion route appears to be a highly efficient 
route of prion transmission46). CWD in deer appears to have an extensive involvement of peripheral tissues50–52) and 
therefore there are many routes by which CWD can be transmitted both within and between species. Understanding the 
distribution of infectivity is therefore an important prerequisite for defining and testing possible routes of transmission.
Adaptation of a Strain within a Host
Once a prion strain has transmitted across a species barrier it generally adapts to its new host and onward transmis-
sion within that host becomes more efficient with a greater number of individuals succumbing to disease and shorter 
incubation times than those observed in the cross species transmission. The ability of a strain to adapt to a new host can 
in part be modelled in transgenic mice or in vitro conversion assays53)(Fig. 2). With multiple lines of mice expressing 
Prnp from different species a single transmission from one species to another can give some indication of the likelihood 
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of transmission to that species. To assess the adaptation further transmissions in the same line of mice often demonstrate 
reductions in incubation times and higher susceptibilities. There is one notable exception to this, however, in vCJD 
which when passed through gene-targeted transgenic mice expressing the human PRNP gene shows no adaptation and 
indeed with passage the numbers of mice showing pathology decreases. This suggests that humans may not be a good 
host for vCJD (Diack, personal communication).
Determining Zoonotic Potential of a prion Agent
To date the only known zoonotic prion agent is BSE, which transmitted to humans as vCJD54,55). Other agents such 
as scrapie have been proposed to be potential zoonotic agents56) and concern over the possibility of CWD transmitting 
to humans has been raised, and the potential for this examined both in vivo57–59) and in vitro60,61). There is no simple 
method to assess the zoonotic potential of a prion, but, knowledge of surveillance, strain identification and potential 
routes of transmission are all important in making such an assessment. Moreover, there are a number of in vivo and in 
vitro systems that can provide useful information to aid in assessing the potential zoonotic risk. The in vitro conversion 
assays using material containing a form of human PrP as a template for misfolding can provide information of the ability 
of human PrP to replicate PrPSc from other species. Indeed the PMCA assay has been used extensively in this respect and 
results from this assay have suggested no barrier to transmission between BSE and CWD, but scrapie does not appear 
to readily amplify human PrP60). However in vitro amplification systems cannot encompass all the elements that make 
up the species barrier and in vivo studies are also an important component of assessing risk. Non-human primates have 
been used for assessing zoonotic potential but the most common and widely used tool is transgenic mice expressing the 
human PRNP gene with different polymorphisms at codon 129. Many different lines of these transgenic mice exist with 
different copy numbers and different sites of integration into the mouse genome. BSE has transmitted to some but not 
all of these mouse lines22,62) and has been transmitted to macaques63,64). Scrapie has also been shown to transmit to mice 
overexpessing the human PrP gene56) and has also been demonstrated to transmit to squirrel monkeys and a cynomol-
gus macaque65,66). Conflicting evidence exists for the transmission of CWD to transgenic mice expressing the human 
PRNP gene and it has been shown to transmit to squirrel monkeys but not macaques67,68). These results therefore pose a 
Fig. 2. Assessing adaptation of a TSE agent in vivo and in vitro. Serial passage through mice dem-
onstrates higher susceptibilities and strain characteristics can be determined. In vitro assays can give a 
biochemical assessment of transmission and adaptation.
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dilemma since all three agents show positivity in at least two assay systems, which, while not proof that transmission to 
humans will occur makes it difficult to rule out the possibility of zoonotic transmission.
Summary
The many elements that make up the species barrier are still not fully understood. However, there are many tools 
within research to examine the possibility of transmission of an agent within and between species. While in vivo studies 
remain an important and vital tool in this assessment, the more recently developed in vitro assay systems provide im-
portant rapid additional information on the replication ability of the agent with different host species and genotypes with 
those species. A combination of both surveillance and strain typing can assist in the identification of new strains and 
compare new strains with old strains. Both in vivo and in vitro studies allow an assessment of the transmission potential 
to different species and the influence of the host genotype on host susceptibility. The potential for zoonotic transmission 
can most fully be assessed using all the tools available and by taking all the evidence from both surveillance and research 
studies into account (Table 1).
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